Erbitux's Numbers Look as Good as in 2001
Editor's note: Adam Feuerstein's coverage of this weekend's ASCO conference will be featured on both RealMoney and TheStreet.com. However, Adam's follow-up analysis and regular biotech commentary appear exclusively on RealMoney. If you're not a regular RealMoney subscriber and are interested in reading more about this sector, please click here for a free trial.
CHICAGO -- Deja vu.
German drug maker Merck KgaA released long-awaited study results today for the experimental cancer drug Erbitux, showing that the drug, when combined with chemotherapy, shrank tumors in patients with late-stage colon cancer. Furthermore, the two-drug combination was more effective than when Erbitux was used alone in the patients, all of who were no longer responding to chemotherapy.
The findings were presented at the annual meeting of the American Society of Clinical Oncology. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |
Connect with TheStreet